The EU’s Rare Disease Lottery: Why Your Treatment Depends on Whether You Live in Ireland, Germany or Malta

Why It Matters

The unequal reimbursement timelines jeopardize patient health and inflate overall EU healthcare costs, making a coordinated policy essential for fairness and efficiency.

Key Takeaways

• 36 million EU citizens live with rare diseases (1 in 12).
• Germany provides orphan drugs in average 97 days; Ireland 695 days.
• Only 13 of 66 approved orphan drugs reimbursed in Ireland.
• Ireland’s 2026 budget earmarks €30 million (~$33 m) for new medicines.
• EU leaders urge a Common Pharmaceutical Policy to end access lottery.

Pulse Analysis

The European Union faces a rare‑disease treatment gap that affects roughly 36 million people, or one in twelve citizens. Orphan drugs—high‑cost therapies for conditions affecting fewer than five in 10,000—must first clear the European Medicines Agency’s scientific review before national health‑technology assessments (HTAs) determine reimbursement. Because each country runs its own HTA, patients experience wildly different timelines: Germany averages just 97 days from approval to access, while Ireland and Malta take 695 and 876 days respectively. This fragmented system not only delays life‑extending care but also creates market inefficiencies as manufacturers navigate divergent pricing rules.

Ireland exemplifies the access challenge. Despite a €30 million (~$33 million) allocation in its 2026 health budget for new medicines—part of a broader €217 million (~$236 million) increase—the country has reimbursed only 13 of the 66 orphan drugs approved EU‑wide between 2020 and 2023. Patients with Friedreich’s Ataxia, such as the author of the source article, still cannot obtain Skyclarys, the sole EMA‑approved therapy for their condition. The lag stems from a “fundamentally broken” reimbursement process that prioritizes cost containment over rapid patient access, prompting criticism from Irish MPs and health officials alike.

Policymakers are now urging a Common Pharmaceutical Policy to replace the national‑by‑national lottery with a unified EU framework. Such a policy would standardize HTA criteria, pool negotiation power, and streamline pricing agreements, potentially cutting average market‑access times by years and ensuring that billions of euros—like the €3 billion (~$3.27 billion) currently spent on medicines—deliver value across all member states. While fiscal pressures and sovereignty concerns remain, the growing consensus is that coordinated action is the only viable path to equitable, timely treatment for rare‑disease patients throughout Europe.